Search research articles
Contact Us
Filters
Showing results (41-50 of 51) with videos related to
Page
of 6
Sort By:
Journal of Medicinal Chemistry
|
November 10, 2007
Discovery of potent & selective inhibitors of activated thrombin-activatable fibrinolysis inhibitor for the treatment of thrombosis
Mark E Bunnage, Julian Blagg, John Steele, et al.
Bioorganic & Medicinal Chemistry Letters
|
September 3, 2011
Discovery of PF-184563, a potent and selective V1a antagonist for the treatment of dysmenorrhoea. The influence of compound flexibility on microsomal stability
Patrick S Johnson, Thomas Ryckmans, Justin Bryans, et al.
Journal of Medicinal Chemistry
|
September 1, 2010
Inhalation by design: novel ultra-long-acting β(2)-adrenoreceptor agonists for inhaled once-daily treatment of asthma and chronic obstructive pulmonary disease that utilize a sulfonamide agonist headgroup
Paul A Glossop, Charlotte A L Lane, David A Price, et al.
Dalton Transactions (Cambridge, England : 2003)
|
July 28, 2004
Synthesis, characterisation and optical spectroscopy of platinum(II) di-ynes and poly-ynes incorporating condensed aromatic spacers in the backbone
Muhammad S Khan, Muna R A Al-Mandhary, Mohammed K Al-Suti, et al.
Bioorganic & Medicinal Chemistry Letters
|
November 16, 2010
Inhalation by design: dual pharmacology β-2 agonists/M3 antagonists for the treatment of COPD
Lyn H Jones, Helen Baldock, Mark E Bunnage, et al.
Journal of Medicinal Chemistry
|
August 30, 2011
Inhalation by design: novel tertiary amine muscarinic M₃ receptor antagonists with slow off-rate binding kinetics for inhaled once-daily treatment of chronic obstructive pulmonary disease
Paul A Glossop, Christine A L Watson, David A Price, et al.
Journal of Medicinal Chemistry
|
March 25, 2010
Discovery of a selective small-molecule melanocortin-4 receptor agonist with efficacy in a pilot study of sexual dysfunction in humans
Mark I Lansdell, David Hepworth, Andrew Calabrese, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
|
April 30, 2020
The association between lithium use and neurocognitive performance in patients with bipolar disorder
Katherine E Burdick, Caitlin E Millett, Manuela Russo, et al.
Bipolar Disorders
|
November 26, 2021
Correction of depression-associated circadian rhythm abnormalities is associated with lithium response in bipolar disorder
Monica Federoff, Michael J McCarthy, Amit Anand, et al.
Molecular Psychiatry
|
March 29, 2023
Focal adhesion is associated with lithium response in bipolar disorder: evidence from a network-based multi-omics analysis
Vipavee Niemsiri, Sara Brin Rosenthal, Caroline M Nievergelt, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 51) with videos related to
Sort By:
Page
of 6
Journal of Medicinal Chemistry
|
November 10, 2007
Discovery of potent & selective inhibitors of activated thrombin-activatable fibrinolysis inhibitor for the treatment of thrombosis
Mark E Bunnage, Julian Blagg, John Steele, et al.
Bioorganic & Medicinal Chemistry Letters
|
September 3, 2011
Discovery of PF-184563, a potent and selective V1a antagonist for the treatment of dysmenorrhoea. The influence of compound flexibility on microsomal stability
Patrick S Johnson, Thomas Ryckmans, Justin Bryans, et al.
Journal of Medicinal Chemistry
|
September 1, 2010
Inhalation by design: novel ultra-long-acting β(2)-adrenoreceptor agonists for inhaled once-daily treatment of asthma and chronic obstructive pulmonary disease that utilize a sulfonamide agonist headgroup
Paul A Glossop, Charlotte A L Lane, David A Price, et al.
Dalton Transactions (Cambridge, England : 2003)
|
July 28, 2004
Synthesis, characterisation and optical spectroscopy of platinum(II) di-ynes and poly-ynes incorporating condensed aromatic spacers in the backbone
Muhammad S Khan, Muna R A Al-Mandhary, Mohammed K Al-Suti, et al.
Bioorganic & Medicinal Chemistry Letters
|
November 16, 2010
Inhalation by design: dual pharmacology β-2 agonists/M3 antagonists for the treatment of COPD
Lyn H Jones, Helen Baldock, Mark E Bunnage, et al.
Journal of Medicinal Chemistry
|
August 30, 2011
Inhalation by design: novel tertiary amine muscarinic M₃ receptor antagonists with slow off-rate binding kinetics for inhaled once-daily treatment of chronic obstructive pulmonary disease
Paul A Glossop, Christine A L Watson, David A Price, et al.
Journal of Medicinal Chemistry
|
March 25, 2010
Discovery of a selective small-molecule melanocortin-4 receptor agonist with efficacy in a pilot study of sexual dysfunction in humans
Mark I Lansdell, David Hepworth, Andrew Calabrese, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
|
April 30, 2020
The association between lithium use and neurocognitive performance in patients with bipolar disorder
Katherine E Burdick, Caitlin E Millett, Manuela Russo, et al.
Bipolar Disorders
|
November 26, 2021
Correction of depression-associated circadian rhythm abnormalities is associated with lithium response in bipolar disorder
Monica Federoff, Michael J McCarthy, Amit Anand, et al.
Molecular Psychiatry
|
March 29, 2023
Focal adhesion is associated with lithium response in bipolar disorder: evidence from a network-based multi-omics analysis
Vipavee Niemsiri, Sara Brin Rosenthal, Caroline M Nievergelt, et al.
Page
of 6